ZBTB34

Across TCGA pan-cancer cohorts, ZBTB34 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZBTB34 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZBTB34 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB34 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, SKCM, and KICH are the cancer types where ZBTB34 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	36	view →
SKCM	DFS	Median	III,IV	1.000	0.457	.007	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZBTB34–SCLC (OS)

Open the SCLC breakdown →